Clinical Characteristics of Epidemic Myalgia Associated with Human Parechovirus Type 3 during the Summer of 2019.
HPeV3
epidemic myalgia
human parechovirus type 3
myositis
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Jul 2020
15 Jul 2020
Historique:
pubmed:
17
4
2020
medline:
24
11
2020
entrez:
17
4
2020
Statut:
ppublish
Résumé
Objective Epidemic myalgia associated with human parechovirus type 3 (EM-HPeV3) is characterized by severe muscle pain and weakness on the limbs and trunk with a fever. No outbreak of EM-HPeV3 has been reported since 2016, and its clinical characteristics have not been sufficiently clarified. We herein report a series of EM-HPeV3 cases during the summer of 2019 and clarify the clinical characteristics of EM-HPeV3. Methods The diagnosis of EM-HPeV3 was established when the patients met both of the following criteria: (1) Patients developed severe muscle pain and weakness with a fever within a week, and those symptoms resolved within a month; and (2) HPeV3 was detected in either a throat swab or fecal specimen of the patient by polymerase chain reaction. We reviewed the medical records of these patients retrospectively. Results Seven patients met the criteria (6 men and 1 woman, age 34 to 47 years old). Myalgia was observed on the thigh, lower legs, upper arms, and forearms in seven, five, two, and five patients, respectively. Four patients showed distal dominant weakness on the arms, while none of the patients showed proximal dominant weakness on the arms. Of the six patients examined, five showed reduced tendon reflexes on all four limbs. One patient showed slight myogenic change and increased insertion activities on needle electromyography. Conclusion We observed seven cases of EM-HPeV3 during the summer of 2019. Reduced tendon reflexes and distal dominancy of muscle pain and weakness on the arms are considered its distinct clinical features.
Identifiants
pubmed: 32296005
doi: 10.2169/internalmedicine.4416-20
pmc: PMC7434534
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1721-1726Références
N Engl J Med. 2012 Jun 14;366(24):2294-304
pubmed: 22694000
Neurology. 1979 Oct;29(10):1323-35
pubmed: 384294
J Med Microbiol. 2015 Nov;64(11):1415-1424
pubmed: 26358716
Emerg Infect Dis. 2012 Nov;18(11):1787-93
pubmed: 23095469
Emerg Infect Dis. 2007 Jun;13(6):889-95
pubmed: 17553229
Infection. 2004 Aug;32(4):199-203
pubmed: 15293074
J Clin Microbiol. 2010 Aug;48(8):2683-8
pubmed: 20519478
Microbiol Immunol. 2016 Dec;60(12):854-858
pubmed: 27925289
J Clin Virol. 2013 Sep;58(1):188-93
pubmed: 23791478
J Clin Virol. 2014 Jun;60(2):84-9
pubmed: 24690382
J Clin Microbiol. 2008 Oct;46(10):3446-53
pubmed: 18753351
Emerg Infect Dis. 2019 Jan;25(1):148-152
pubmed: 30561318
Muscle Nerve. 2015 May;51(5):638-56
pubmed: 25641317
J Gen Virol. 2004 Feb;85(Pt 2):391-398
pubmed: 14769896
Clin Neurophysiol. 2015 Dec;126(12):2376-80
pubmed: 25743269
Clin Microbiol Rev. 2008 Jul;21(3):473-94
pubmed: 18625683
Epidemiol Infect. 2016 Apr;144(6):1286-90
pubmed: 26584624
J Infect. 2016 Feb;72(2):223-32
pubmed: 26550926
Phys Ther. 1992 Feb;72(2):115-22; discussion 122-6
pubmed: 1549632
J Microbiol Immunol Infect. 2004 Apr;37(2):95-8
pubmed: 15181490
J Neurol Sci. 2011 Jan 15;300(1-2):14-8
pubmed: 21081241
J Clin Virol. 2012 Jun;54(2):156-61
pubmed: 22406272
J Coll Gen Pract. 1961 May;4:181-213
pubmed: 13785530
Rinsho Shinkeigaku. 2017 Sep 30;57(9):485-491
pubmed: 28855493